Study Initiated to Assess Feasibility of Online Recruitment for Semaglutide, Tirzepatide Users
Background
Obesity is a complex chronic disease requiring long-term management, often with anti-obesity medications (AOMs) like semaglutide and tirzepatide. Traditional clinical research recruitment can be slow and geographically limited, hindering the rapid understanding of real-world AOM effects and patient experiences. Digital research communities offer a promising avenue to efficiently engage diverse populations, but their effectiveness for specific cohorts, especially those using prescription medications for weight loss, needs validation for consent and data collection, including at-home biosampling.
Study Design
This observational study is actively recruiting participants from a digital research community who are using anti-obesity medications, specifically semaglutide or tirzepatide, for weight loss. The study's design focuses on assessing the feasibility of online recruitment and participant willingness to consent to survey research and complete at-home self-blood testing. Participants will engage in various digital tasks, including health-related surveys and the self-collection of capillary blood samples for assay testing. The study does not prescribe medication; it observes individuals already using AOMs, aiming to validate digital engagement and data collection methods.
Results
As this study is currently in the recruiting phase (NCT ID: NCT06790160, started 2025-01-31), no specific findings regarding recruitment feasibility, consent rates, or self-blood testing completion are available yet. The study is designed to gather data on the willingness of participants from an active digital community to engage in a digital study, provide consent, and successfully complete tasks such as health surveys and self-collected capillary blood samples for assay testing. Future results will quantify these engagement metrics to determine the overall feasibility of this online recruitment approach for real-world evidence generation in the obesity treatment landscape.
Key Findings
- Study is currently recruiting; no findings available yet.
- Aims to quantify willingness to consent for surveys.
- Aims to quantify completion rates for at-home blood tests.
Why It Matters
Successful online recruitment for studies involving anti-obesity medications like semaglutide and tirzepatide could significantly accelerate real-world evidence generation. This approach could enable faster insights into long-term AOM efficacy, safety, and patient-reported outcomes, reaching diverse populations beyond traditional clinical sites. For peptide users and biohackers, this methodology could pave the way for more accessible research participation, potentially influencing future protocols by providing a broader dataset on how these compounds perform in varied real-world settings. It could also validate the use of at-home biosampling, making research less burdensome and more inclusive.
online-recruitment
observational-study
semaglutide
tirzepatide
obesity
weight-loss
